萊斯康製藥 LXRX 深 滬
等待開盤 11-26 09:30:00 美东时间
1.41
-0.010
-0.70%
華盛通- 最 高1.44
- 今 開1.44
- 成交量 116.82万股
- 最 低 1.37
- 昨 收 1.42
- 總市值 5.12亿
- 52周最高 1.66
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 0.2836
- 委 比 -48.17%
- 總股本 3.63亿
- 歷史最高 22.96
- 量 比 0.68
- 振 幅 4.93%
- 歷史最低 0.2836
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
Lexicon Pharmaceuticals announced that its management will participate in fireside chats at the Piper Sandler 37th Annual Healthcare Conference on December 3 and the 8th Annual Evercore Healthcare Conference on December 4. Links to live events and replays are available on the company's website. Lexicon is a biopharmaceutical company focused on pioneering medicines through its Genome5000 program, advancing treatments for diseases like heart failur...
11-25 13:30
SeaStar Medical Announces Appointment of Michael Messinger as CFO
SeaStar Medical announced the appointment of Michael Messinger as Chief Financial Officer. With over 25 years of experience in healthcare finance, Mr. Messinger previously led ContraFect Corporation through its IPO and financings. SeaStar Medical specializes in treating critically ill patients with organ failure, particularly through its FDA-approved QUELIMMUNE therapy for pediatric AKI. The company is expanding its SCD therapy for multiple indic...
11-17 13:43
Lexicon Pharmaceuticals Files Prospectus for Stock Sale
Lexicon Pharmaceuticals ( ($LXRX) ) has issued an update. On November 6, 2025, ...
11-07 06:52
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Lexicon Pharmaceuticals reported Q3 2025 financial results with total revenue increasing to $14.2M, driven by $13.2M in licensing revenue from the Novo Nordisk agreement. R&D expenses decreased to $18.8M, while SG&A expenses fell to $7.6M. The company achieved a net loss of $12.8M compared to $64.8M in Q3 2024. Key milestones include scheduling an End-of-Phase 2 meeting for pilavapadin, completing LX9851 IND-enabling studies, advancing sotagliflo...
11-06 12:30
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Lexicon Pharmaceuticals will release its Q3 2025 financial results on November 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update. Participants can access the call via webcast on the company’s website or register to receive dial-in details. Lexicon is a biopharmaceutical company focused on pioneering medicines through its Genome5000™ program, targeting proteins with therapeutic ...
10-30 12:30
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
Lexeo Therapeutics announced an underwritten public offering and concurrent private placement, raising approximately $135 million in gross proceeds. The company offered 15,625,000 shares of common stock at $8.00 per share, with an option for underwriters to purchase an additional 2,343,750 shares. Additionally, Lexeo sold pre-funded warrants for 1,250,015 shares of common stock to Balyasny Asset Management at $7.9999 per warrant in a private plac...
10-17 03:29
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Lexicon Pharmaceuticals announced Phase 2 data supporting the advancement of 10 mg pilavapadin into Phase 3 development for diabetic peripheral neuropathic pain (DPNP). The U.S. FDA accepted the company's request for an end-of-Phase 2 meeting, and discussions with potential partners are progressing. Key findings include validated biological activity, clinically meaningful efficacy (2-point ADPS reduction), and acceptable tolerability and safety p...
10-14 12:00
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Lexicon hosted a roundtable to discuss improving access to non-opioid treatments and expanding legislation like the Alternatives to PAIN Act for chronic pain patients. The meeting focused on addressing the high impact of chronic pain, affecting 50 million Americans, and highlighted the need for innovative therapies and policy changes.
10-08 11:59
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
In the PROGRESS Phase 2b study, Lexicon Pharmaceuticals' investigational AAK1-inhibitor, pilavapadin, showed a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 for the treatment of diabetic peripheral neuropathic pain (DPNP). The 10 mg dose was well-tolerated and identified as the most clinically meaningful dose. Results were presented at the NEUROdiab and EASD Annual Meetings, highlighting pilavapadin's potential ...
09-17 11:00
